Literature DB >> 31267715

VE-PTP inhibition stabilizes endothelial junctions by activating FGD5.

Laura J Braun1, Maren Zinnhardt1, Matthias Vockel1, Hannes C Drexler1, Kevin Peters2, Dietmar Vestweber1.   

Abstract

Inhibition of VE-PTP, an endothelial receptor-type tyrosine phosphatase, triggers phosphorylation of the tyrosine kinase receptor Tie-2, which leads to the suppression of inflammation-induced vascular permeability. Analyzing the underlying mechanism, we show here that inhibition of VE-PTP and activation of Tie-2 induce tyrosine phosphorylation of FGD5, a GTPase exchange factor (GEF) for Cdc42, and stimulate its translocation to cell contacts. Interfering with the expression of FGD5 blocks the junction-stabilizing effect of VE-PTP inhibition in vitro and in vivo. Likewise, FGD5 is required for strengthening cortical actin bundles and inhibiting radial stress fiber formation, which are each stimulated by VE-PTP inhibition. We identify Y820 of FGD5 as the direct substrate for VE-PTP. The phosphorylation of FGD5-Y820 is required for the stabilization of endothelial junctions and for the activation of Cdc42 by VE-PTP inhibition but is dispensable for the recruitment of FGD5 to endothelial cell contacts. Thus, activation of FGD5 is a two-step process that comprises membrane recruitment and phosphorylation of Y820. These steps are necessary for the junction-stabilizing effect stimulated by VE-PTP inhibition and Tie-2 activation.
© 2019 The Authors.

Entities:  

Keywords:  zzm321990RPTPzzm321990; Tie-2; cell adhesion; junctions; vascular permeability

Mesh:

Substances:

Year:  2019        PMID: 31267715      PMCID: PMC6607018          DOI: 10.15252/embr.201847046

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  50 in total

1.  Universal sample preparation method for proteome analysis.

Authors:  Jacek R Wiśniewski; Alexandre Zougman; Nagarjuna Nagaraj; Matthias Mann
Journal:  Nat Methods       Date:  2009-04-19       Impact factor: 28.547

2.  Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2.

Authors:  G Fachinger; U Deutsch; W Risau
Journal:  Oncogene       Date:  1999-10-21       Impact factor: 9.867

3.  Rasip1 mediates Rap1 regulation of Rho in endothelial barrier function through ArhGAP29.

Authors:  Anneke Post; Willem-Jan Pannekoek; Sarah H Ross; Ingrid Verlaan; Patricia M Brouwer; Johannes L Bos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

4.  Dimerization inhibits the activity of receptor-like protein-tyrosine phosphatase-alpha.

Authors:  G Jiang; J den Hertog; J Su; J Noel; J Sap; T Hunter
Journal:  Nature       Date:  1999-10-07       Impact factor: 49.962

5.  Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization.

Authors:  A M Bilwes; J den Hertog; T Hunter; J P Noel
Journal:  Nature       Date:  1996-08-08       Impact factor: 49.962

6.  Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions.

Authors:  J R Gamble; J Drew; L Trezise; A Underwood; M Parsons; L Kasminkas; J Rudge; G Yancopoulos; M A Vadas
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

7.  Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis.

Authors:  Sofie Mellberg; Anna Dimberg; Fuad Bahram; Makoto Hayashi; Emma Rennel; Adam Ameur; Jakub Orzechowski Westholm; Erik Larsson; Per Lindahl; Michael J Cross; Lena Claesson-Welsh
Journal:  FASEB J       Date:  2009-01-09       Impact factor: 5.191

8.  Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo.

Authors:  Tadanori Mammoto; Samir M Parikh; Akiko Mammoto; Diana Gallagher; Barden Chan; Gustavo Mostoslavsky; Donald E Ingber; Vikas P Sukhatme
Journal:  J Biol Chem       Date:  2007-06-11       Impact factor: 5.157

9.  VE-PTP controls blood vessel development by balancing Tie-2 activity.

Authors:  Mark Winderlich; Linda Keller; Giuseppe Cagna; Andre Broermann; Olena Kamenyeva; Friedemann Kiefer; Urban Deutsch; Astrid F Nottebaum; Dietmar Vestweber
Journal:  J Cell Biol       Date:  2009-05-18       Impact factor: 10.539

10.  VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation.

Authors:  Makoto Hayashi; Arindam Majumdar; Xiujuan Li; Jeremy Adler; Zuyue Sun; Simona Vertuani; Carina Hellberg; Sofie Mellberg; Sina Koch; Anna Dimberg; Gou Young Koh; Elisabetta Dejana; Heinz-Georg Belting; Markus Affolter; Gavin Thurston; Lars Holmgren; Dietmar Vestweber; Lena Claesson-Welsh
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  5 in total

1.  Vascular Endothelial Receptor Tyrosine Phosphatase: Identification of Novel Substrates Related to Junctions and a Ternary Complex with EPHB4 and TIE2.

Authors:  Hannes C A Drexler; Matthias Vockel; Christian Polaschegg; Maike Frye; Kevin Peters; Dietmar Vestweber
Journal:  Mol Cell Proteomics       Date:  2019-08-19       Impact factor: 5.911

2.  Platelets docking to VWF prevent leaks during leukocyte extravasation by stimulating Tie-2.

Authors:  Laura J Braun; Rebekka I Stegmeyer; Kerstin Schäfer; Stefan Volkery; Silke M Currie; Birgit Kempe; Astrid F Nottebaum; Dietmar Vestweber
Journal:  Blood       Date:  2020-07-30       Impact factor: 22.113

3.  Fgd5 is a Rac1-specific Rho GEF that is selectively inhibited by aurintricarboxylic acid.

Authors:  Sally Park; Yitian Guo; Judeah Negre; Jordane Preto; Cameron C Smithers; Abul Kalam Azad; Michael Overduin; Allan G Murray; Gary Eitzen
Journal:  Small GTPases       Date:  2019-10-10

Review 4.  Permeability of the Endothelial Barrier: Identifying and Reconciling Controversies.

Authors:  Lena Claesson-Welsh; Elisabetta Dejana; Donald M McDonald
Journal:  Trends Mol Med       Date:  2020-12-10       Impact factor: 11.951

5.  Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma.

Authors:  Benjamin R Thomson; Isabel A Carota; Tomokazu Souma; Saily Soman; Dietmar Vestweber; Susan E Quaggin
Journal:  Elife       Date:  2019-10-17       Impact factor: 8.140

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.